Protagonist Therapeutics enters deal for rusfertide with Takeda

1 February 2024

Clinical-stage US pharma company Protagonist Therapeutics' (Nasdaq: PTGX) shares rose 6% to $26.5O in early trading, on news of a licensing deal for its blood disorder candidate rusfertide.

The company signed a worldwide license and collaboration agreement with Japan’s largest drugmaker, Takeda (TYO: 4502), for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase III trial, VERIFY, for the treatment of polycythemia vera (PV).

PV is a rare chronic blood disorder characterized by excessive production of red blood cells that affects as many as 160,000 patients in the USA, with a similar prevalence in Europe. The hallmark manifestations of PV are increased red blood cell count and iron deficiency, putting patients at higher risk of cardiovascular and thrombotic events, such as heart attack and stroke, often impacting quality-of-life with symptoms such as fatigue and confusion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK